Yes, Pluvicto Is a Radiopharmaceutical
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapy approved by the FDA for treating prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer.[1] It combines the radioactive isotope lutetium-177 (Lu-177), which emits beta particles to damage cancer cells, with a targeting ligand (vipivotide tetraxetan) that binds to PSMA on tumor cells.[2]
How Does Pluvicto Work?
Lu-177 delivers targeted radiation directly to PSMA-expressing cancer cells, minimizing exposure to healthy tissue. It's administered via intravenous injection, typically every 6 weeks for up to 6 cycles, after confirming PSMA positivity with a PET scan.[1][3]
What Makes It Different from Chemotherapy?
Unlike traditional chemotherapy, which affects all rapidly dividing cells systemically, Pluvicto's radiopharmaceutical design enables precise tumor targeting, reducing some side effects like hair loss while still causing fatigue, dry mouth, and kidney risks.[2]
Common Side Effects Patients Report
Dry mouth (from salivary gland exposure), nausea, fatigue, anemia, and decreased appetite occur in over 10% of patients. Long-term risks include kidney damage and bone marrow suppression.[1][3]
Who Makes Pluvicto and What's the Cost?
Novartis manufactures and markets Pluvicto. A single dose costs around $43,000-$50,000, with full treatment courses exceeding $200,000 depending on cycles and location.[4] Medicare covers it for eligible patients.
When Did FDA Approval Happen?
FDA granted accelerated approval in March 2022 based on the VISION trial, showing 38% lower death risk versus standard care. Full approval came in 2025 after confirmatory data.[1][2]
Patent and Generic Timeline
Pluvicto's key patents, held by Novartis and Advanced Accelerator Applications, extend exclusivity through at least 2037, with some challenged in ongoing litigation. No generics or biosimilars are approved yet.5
[1]: FDA.gov - Pluvicto Label (https://www.accessdata.fda.gov/drugsatfdadocs/label/2022/761207s000lbl.pdf)
[2]: Novartis.com - Pluvicto Overview (https://www.novartis.com/us-en/sites/novartisus/files/pluvicto.pdf)
[3]: NEJM - VISION Trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2107322)
[4]: ICER Report (https://icer.org/wp-content/uploads/2023/05/ICERPSMATherapies_2023.pdf)